Citius Oncology has entered a senior secured credit facility with Avenue Capital Group for up to $25 million, including an initial $10 million tranche, to support the commercialization of its FDA-approved cancer drug LYMPHIR. Concurrently, the company raised approximately $11.5 million through the exercise of warrants by a healthcare-focused investor. These financings provide Citius Oncology with enhanced financial flexibility to expand sales, market access, and manufacturing efforts for LYMPHIR, targeting relapsed or refractory cutaneous T-cell lymphoma. The funds will also support working capital and general corporate purposes as the company scales its commercial infrastructure.
Law Offices of Howard G. Smith reminds investors of upcoming deadlines to file lead plaintiff motions in securities fraud class actions involving Badger Meter, PicS N.V., Verra Mobility, and Grail, Inc. The lawsuits allege these companies made mislea...
Assembli Events & Production is creating the Big Ten Conference's first fan activation at Fanatics Fest NYC, held July 16-19, 2026. This event marks the Big Ten as the first collegiate conference to join the premier sports fan festival, showcasing tr...
State Street posted strong Q2 results with earnings per share of $3.65, beating estimates and up from $2.53 last year. Quarterly revenue reached $4.05 billion, driven by a 17.2% rise in fee revenues and 18% growth in net interest income. Assets under...
U.S. farmers face high and unstable fertilizer prices due to global shipping disruptions, with nearly 70% unable to afford needed fertilizer this season. Denali Water Solutions provides a natural, low-cost fertilizer alternative made from recycled or...
Denodo Technologies released Platform 9.5, improving its AI data layer by providing trusted, governed enterprise context for AI, analytics, and data sharing. Key features include an expanded enterprise knowledge graph, metric views for consistent bus...
